

## Main hall

<b>Diagnosis</b>					
OP01	Day 1	10:15-10:30	In vivo monitoring of nerve lesions in symptomatic hATTR and asymptomatic gene carriers by new imaging biomarkers	Kollmer, Jennifer	Heidelberg, Germany
OP02	Day 1	10:30-10:45	Genetic diagnosis in ATTR amyloidosis; a single UK Centre 25 year experience.	Rowczenio, Dorota	London, United Kingdom
OP03	Day 1	10:45-11:00	Utility of a quantitative and targeted proteomic analysis of fat tissue in systemic amyloidoses using a selected reaction monitoring (SRM)-MS assay	Hazenberg, Bouke P	Groningen, Netherlands
OP04	Day 1	11:00-11:15	Development of Response to Therapy and Disease Specific Biomarkers for the Hereditary Transthyretin Amyloidoses	Monteiro, Cecilia	La Jolla, United States
<b>Basic research 1</b>					
OP13	Day 1	11:15-11:30	Seed-Directed Imprinting of Insulin Amyloid Fibrils: from the Obvious to the Mysterious	Dzwolak, Wojciech	Warsaw, Poland
OP14	Day 1	11:30-11:45	Amyloidosis due to natural apolipoprotein A-I Variants. Mechanisms involved in the pathogenicity pathways	Tricerri, M. Alejandra	la Plata, Argentina
OP15	Day 1	11:45-12:00	Interaction of TTR and SERPINA1 in ATTR Amyloidosis	Niemietz, Christoph	Münster, Germany
OP16	Day 1	12:00-12:15	Photo-Controllable Probe Spatiotemporally Induces Neurotoxic Aggregates in Neurodegenerative Disease	Huang, Jen-Tse	Taipei, Taiwan
OP17	Day 1	12:15-12:30	Inhibitors of Paradigmatic Amyloidogens	Esposito, Gennaro	Udine, Italy
<b>Hereditary ATTR amyloidosis 1</b>					
OP05	Day 1	15:00-15:15	Clinical paradigms in treatment effectiveness for hereditary transthyretin amyloidosis	Costa, João	Lisboa, Portugal
OP06	Day 1	15:15-15:30	Liver transplantation for hereditary transthyretin amyloidosis (hATTR) in Spain - 25-year experience	Gonzalez, Esther	Alcala de Henares, Spain
OP07	Day 1	15:30-15:45	The 2017 year Domino Liver Transplant Register (DLTR) status on the use of Livers with Metabolic Disorders for Transplantation. Do Novel AntiAmyloidosis Drugs Have A Role in Domino Liver Transplant (DLT) Recipients?	Ericzon, Bo Göran	Stockholm, Sweden
OP08	Day 1	15:45-16:00	The cross-talk between Ocular and Central Nervous System phenotypes in ATTR V30M patients	Maia, Luís	Porto, Portugal
<b>ATTR amyloidosis 3</b>					
OP18	Day 2	8:50-9:05	Penetrance variation in Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) with 7 ATTR variants observed in Europe	Plante-Bordeneuve, Violaine	Créteil, France
OP19	Day 2	9:05-9:20	Characteristics of TTR fragmentation pattern in ATTR patients carrying various mutations	Tasaki, Masayoshi	Pavia, Italy
OP20	Day 2	9:20-9:35	Altered gene regulation in wild-type transthyretin (ATTRwt) amyloidosis caused by genetic risk variant, rs72922940	Maenpaa, Eila	Boston, United States

OP21	Day 2	9:35-9:50	Refine penetrance estimates in Swedish ATTR-Val30Met kindreds	Olsson, Malin	Umeå, Sweden
------	-------	-----------	---	---------------	--------------

## Pathology

OP22	Day 2	11:20-11:35	Cryo-electron microscopy structures of cross- $\beta$ fibrils	Fändrich, Marcus	Ulm, Germany
OP23	Day 2	11:35-11:50	Evaluation of LDMS for diagnostic use at a Large Referral Centre	Gilbertson, Janet A	London, United Kingdom
OP24	Day 2	11:50-12:05	Noninvasive screening method for ATTRm amyloidosis by using fat ultrasonography	Misumi, Yohei	Kumamoto, Japan

## AL amyloidosis 2

OP29	Day 2	14:30-14:45	Predictors of hematologic and organ response in AL amyloidosis	Palladini, Giovanni	Pavia, Italy
OP30	Day 2	14:45-15:00	Depth of organ response in AL amyloidosis is associated with improved survival: New proposed organ response criteria	Muchtar, Eli	Rochester, United States
OP31	Day 2	15:00-15:15	Stem Cell Transplantation for AL Amyloidosis- Reduced mortality over time with 20 year survivors	Sidiqi, M Hasib	Rochester, United States
OP32	Day 2	15:15-15:30	Salvage Lenalidomide-based Therapy for Patients With AL Amyloidosis	Kastritis, Efsthios	Athens, Greece

## AL amyloidosis 3

OP37	Day 2	16:00-16:15	Daratumumab monotherapy in forty-eight heavily pretreated patients with advanced systemic light-chain amyloidosis	Kimmich, Christoph R	Heidelberg, Germany
OP38	Day 2	16:15-16:30	EGCG Treatment In Patients With Cardiac AL Amyloidosis: First Results Of A Randomized And Placebo-Controlled Clinical Trial of GERAMY	Hegenbart, Ute	Heidelberg, Germany
OP39	Day 2	16:30-16:45	One Year Follow Up Analysis of the Phase 1a/b Study of Chimeric FibrilReactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis	Edwards, Camille V.	Boston, United States
OP40	Day 2	16:45-17:00	Effective Lipidoid Nanoparticle Delivery In Vitro and In Vivo of siRNA Targeting Ig Light Chain mRNA in Clonal Plasma Cells	Ma, Xun	Boston, United States

## Basic research and animal models

OP33	Day 3	9:20-9:35	Organ-specificity of Apolipoprotein A-I amyloidogenic variants: the role of the extracellular environment	Del Giudice, Rita	Lund, Sweden
OP34	Day 3	9:35-9:50	Amyloid seeding of transthyretin caused by ATTR cardiac fibrils and its inhibition	Saelices, Lorena	Los Angeles, United States
OP35	Day 3	9:50-10:05	Degeneration of sensory nerves in a Knock-in Mouse Model of Transthyretin(Ala97Ser) Amyloid Neuropathy	Hsieh, Sung-Tsang	Taipei, Taiwan
OP36	Day 3	10:05-10:20	Modeling amyloidogenic LC proteotoxicity in zebrafish	Ward, Jennifer	Boston, United States

## Wild-type ATTR amyloidosis

OP41	Day 3	10:50-11:05	Prevalence and severity of peripheral and autonomic neuropathy in THAOS subjects with wild-type or hereditary transthyretin cardiac amyloidosis	Khella, Sami L.	Philadelphia, United States
OP43	Day 3	11:05-11:20	Is lumbar spinal stenosis an early sign of systemic ATTR amyloidosis?	Eldhagen, Per A	Stockholm, Sweden
OP42	Day 3	11:20-11:35	Effect of TTR tetramer stabilizing agents on clusterin levels in ATTRwt amyloidosis	Torres-Arancivia, Celia	Boston, United States
OP44	Day 3	11:35-11:50	Structural studies on ATTRwt serum clusterin	Torres-Arancivia, Celia	Boston, United States
OP66	Day 3	11:50-12:05	Transthyretin inhibition of amyloidogenesis in vitro and in vivo: protein-protein interactions across biologic kingdoms	Buxbaum, Joel N.	La Jolla, United States

## Cardiac amyloidosis

OP45	Day 3	14:30-14:45	Cardiac amyloidosis in Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey	Damy, Thibaud	Créteil, France
OP46	Day 3	14:45-15:00	99mTc-DPD Scintigraphy Is An Independent Predictor Of Outcomes In Cardiac AL Amyloidosis	Wechalekar, Ashutosh	London, United Kingdom
OP47	Day 3	15:00-15:15	Transthyretin amyloidosis cardiomyopathy: Genotype, phenotype, natural history and quality of life in 1034 patients seen at the UK national referral centre in the UK	Gillmore, Julian	London, United Kingdom
OP48	Day 3	15:15-15:30	AL amyloidosis cardiac staging systems retain their important prognostic value also in patients with impaired renal function and atrial fibrillation	Dittrich, Tobias	Heidelberg, Germany

## Proteinopathies and other types of amyloidosis

OP53	Day 3	16:00-16:15	Aggregated alpha-synuclein is spread via tunnelling nanotubes in cultured human astrocytes	Bergstrom, Joakim	Uppsala, Sweden
OP54	Day 3	16:15-16:30	Amyloid polymorphism and cell specific toxicity in vivo	Hammarstrom, Per	Linkoping, Sweden
OP55	Day 3	16:30-16:45	Structural bases of gelsolin amyloidosis	de Rosa, Matteo	Milano, Italy
OP56	Day 3	16:45-17:00	Isolated Amyloid Myopathy: An Emerging Group of Hereditary Localized Amyloidosis	Liewluck, Teerin	Rochester, United States

## AA amyloidosis

OP09	Day 4	9:20-9:35	Effect of Carboxyl-Terminal Truncation on Amyloid Fibril Formation of Human Serum Amyloid A	Tanaka, Masafumi	Kobe, Japan
OP10	Day 4	9:35-9:50	Systemically conserved pathways of protein misfolding in vivo	Loos, Cornelia	Ulm, Germany
OP11	Day 4	9:50-10:05	Cellular mechanism of fibril formation from serum amyloid A1 protein	Puscalau-Girtu, Ioana	Ulm, Germany
OP12	Day 4	10:05-10:20	Obesity as a cause of AA amyloidosis: a case series of 15 patients	Georgin-Lavialle, Sophie	Paris, France

## CAA and other brain amyloidosis

OP62	Day 4	10:50-11:05	Sushi repeat-containing protein 1 co-accumulates with cerebrovascular A $\beta$ deposits in cerebral amyloid angiopathy	Inoue, Yasuteru	Kumamoto, Japan
OP63	Day 4	11:05-11:20	Visualization of Amyloid beta deposits in human brain with MALDI Imaging Mass Spectrometry	Ikegawa, Masaya	Kyotanabe, Japan
OP64	Day 4	11:20-11:35	Bri2 BRICHOS is a multifunctional chaperone with activity against amyloid formation as well as non-fibrillar aggregation	Johansson, Jan	Huddinge, Sweden
OP65	Day 4	11:35-11:50	Amyloid aggregation of alpha-synuclein and prion protein can be controlled using polyanions	Semenyuk, Pavel	Moscow, Russia

## 2nd hall

<b>AL amyloidosis 1</b>					
OP25	Day 2	9:50-10:05	Outcomes of autologous hematopoietic cell transplantation versus chemotherapy alone in patients with light-chain amyloidosis	Miyazaki, Kanji	Tokyo, Japan
OP26	Day 2	10:05-10:20	Differences in mutational hotspots in AL amyloidosis kappa and lambda light chains	Ramirez-Alvarado, Marina	Rochester, United States
OP27	Day 2	10:20-10:35	AL Amyloidosis is Phenotypically Different from Multiple Myeloma due to Internal Amyloidogenic Light Chain Toxicity	Gatt, Moshe	Jerusalem, Israel
OP28	Day 2	10:35-10:50	Small molecule stabilizers of amyloidogenic antibody light chains	Morgan, Gareth J	La Jolla, United States
<b>Basic Research 2</b>					
OP49	Day 3	14:00-14:15	Serum Amyloid P component nanobodies, a new tool in amyloid research	Gettemans, Jan	Ghent, Belgium
OP50	Day 3	14:15-14:30	Larger normal repeats of ATXN2 gene may decrease age-at-onset in Portuguese familial amyloid polyneuropathy (TTR-FAP Val30Met) patients	Santos, Diana	Porto, Portugal
OP51	Day 3	14:30-14:45	Proteasome regulates turnover of toxic human islet amyloid polypeptide	Jeremic, Aleksandar	Washington, United States
OP52	Day 3	14:45-15:00	Variants in the transthyretin gene region as modulators of disease expressivity	Alves-Ferreira, Miguel	Porto, Portugal
<b>Epidemiology</b>					
OP57	Day 3	15:00-15:15	The Epidemiology of Amyloidosis in Australia	Mollee, Peter	Brisbane, Australia
OP58	Day 3	15:15-15:30	Geographic distribution of ATTR cases from CEPARM (Centro de Estudos em Paramiloidose Antônio Rodrigues de Mello) across the Brazilian territory and their clinical aspects, demographics, ethnical and family background.	Waddington-Cruz, Márcia	Rio De Janeiro, Brazil
OP59	Day 3	15:30-15:45	A descriptive analysis of subjects with the Ser50Arg mutation enrolled in the Transthyretin Amyloidosis Outcomes Survey	Gonzalez-Duarte, Alejandra	Mexico City, Mexico
OP60	Day 3	15:45-16:00	Features and changes in AA amyloidosis in Japan	Yamada, Toshiyuki	Shimotsuke, Japan
OP61	Day 3	16:00-16:15	Increased risk of multiple outpatient surgery in carriers of TTR V122I mutation in a relatively young cohort of 4,361 African-Americans	Polimanti, Renato	West Haven, United States